Redirecting to https://www.wallstreet-online.de/nachricht/20925738-junshi-biosciences-announces-primary-endpoints-met-final-analysis-of-phase-3-study-for-perioperative-toripalimab-plus-chemotherapy-for-resectable-stage-ii-iii-nsclc